(VIANEWS) – Atrion (ATRI) Stock Gains 32.07% in Two Weeks – Recoup Losses
Atrion (NASDAQ: ATRI) shares have experienced an extraordinary turnaround over the last 21 sessions, increasing by 32.07% from EUR340.16 on February 22, 2024 to EUR449.25 at 12:27 EST on Wednesday March 8th at 12:27 ET. Following two consecutive days of losses, Atrion quickly made up its ground and reversed its fortunes.
Atrion fell by 0.04% to EUR16,161.04 during this same timeframe; even with recent recoveries in its stock price, Atrion remains down 36.03% from its 52-week high of EUR670.00.
About Atrion
Atrion Corporation is a developer, manufacturer and seller of fluid delivery, cardiovascular and ophthalmic products used in various medical applications across North America, Europe and internationally. Fluid Delivery Products provided by the company include valves designed for intubation, intravenous, catheterization and other applications in anesthesia and oncology as well as infection control in hospital and home healthcare environments. Atrion’s cardiovascular products include its Myocardial Protection System, cardiac surgery vacuum relief valves, silicone vessel loops and inflation devices for balloon catheter dilation, stent deployment and fluid dispensing. Ophthalmic products offered by the company include balloon catheters designed to treat nasal-lacrimal duct obstruction. Atrion manufactures products designed for safe needle and scalpel blade containment, marine safety products like inflation systems and valves used in marine rescue efforts, components used in inflatable survival products and structures, pressure relief valves used for transport of electronics during medical or non-medical transport applications and pressure relief valves that protect sensitive electronics in medical transport environments. Atrion Corporation was established in 1944 and is currently headquartered in Allen, Texas. Their products are offered to physicians, hospitals, clinics, treatment centers as well as equipment manufacturers through direct sales force personnel, independent sales representatives and distributors.
Yearly Analysis
As a financial expert, I conducted an analysis on Atrion stock and can offer the following investment outlook based on its data:
Yearly Top and Bottom Value Atrion’s stock is currently trading at EUR449.25, significantly below its 52-week high of EUR670.00 but higher than its 52-week low of EUR274.98 – suggesting both significant decline and recovery during this past year.
Atrion’s Earnings Before Interest, Taxes, Depreciation and Amortization for the past year was EUR4.55. This figure provides insight into their profitability; however, without additional financial data it would be difficult to assess their overall financial health.
Based on this analysis, it appears that Atrion stock has experienced significant decline over the past year but is slowly recovering. Unfortunately, without additional financial information it is impossible to provide a complete investment outlook and investors should conduct further investigation of Atrion’s finances, growth prospects, and industry trends before making any definitive investment decisions.
Technical Analysis
Atrion stock prices are currently trading above both their 50-day and 200-day moving averages, signaling bullish behavior both short- and long-term. This indicates an optimistic trend and suggest the stock is likely to maintain its upward momentum. This bodes well for investors looking for investment opportunities.
However, its volume has recently fallen below its usual trading activity levels indicating reduced trading activity relative to usual. This could suggest investors lack of conviction in its future value which may cause its price to decrease further.
Atrion’s current intraday variation average is relatively low, averaging just 0.56% over the last week, 1.50% over the past month and 3.34% since quarter end – this indicates its price has been relatively stable but with potential for higher volatility over time.
Though Atrion’s bullish trend is promising, investors must ensure its positive momentum is sustained by monitoring volume and volatility levels of its shares.
Quarter Analysis
This section presents an overview of the company’s revenue growth, which has increased by 1.7% year-on-year over its twelve trailing months to an annualized revenue totaling 169.33M. This information should provide investors with a quick understanding of both financial performance and revenue trends for this company.
Equity Analysis
Atrion currently boasts an estimated forward annual dividend rate of EUR8.8 per share and market price of EUR434.550 as of February 28, 2023; their next scheduled payment date for this dividend payment is set for Mar 14, 2024. Earnings Per Share
Atrion Group’s trailing twelve months EPS stands at EUR11.02, representing its earnings per outstanding share over the past year. Atrion also boasts a PE ratio of 0.81.
Atrion’s P/E ratio of 40.77 indicates that investors are willing to pay EUR40.77 for every euro of annual earnings – suggesting it may be overvalued compared to its historical average. Return on Equity
Atrion’s 12-month return on equity (ROE) stands at 8.05%, meaning they generated 8.05 cents of profit per EUR1 of shareholder equity invested. This indicates a relatively low rate, which may indicate potential undervaluation or increased profitability needs. Key Financial Ratios and Stock Performance.
Here is some key financial ratios and stock performance data for Atrion: Whilst market capitalization stands at EUR2.06 billion, its price to earnings ratio (TTM) stands at 40.77. Its ROE (TTM) stands at 8.05% while dividend yield stands at 2.01% – with 52-week range between EUR352.00 – EUR434.550 during 52 weeks ranging between negative -4.7% return year on year and positive 104% overall returns over five years.
Ten-Year Return: 173.2%
Please keep in mind that the data presented here was as of February 28th 2023 and may no longer accurately represent current market conditions. In addition, this analysis does not constitute financial, investment or any other professional advice and you should always conduct further research or consult a financial expert prior to making any investment decisions.
More news about Atrion (ATRI).
